[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"percutaneous-coronary-intervention\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:percutaneous-coronary-intervention":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,61,0,25,[9,50,63,101,131,162,186,207,238,254,273,301,352,387,414,438,462,489,515,536,559,575,602,625,650],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100053769","phase-4-inclisiran-versus-placebo-for-the-prevention-of-major-adverse-cardiovascular-and-limb-events-in-patients-undergoing-percutaneous-coronary-intervention-or-peripheral-endovascular-intervention-100053769",false,"NCT06909565","Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention","Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION)","V-INTERVENTION","Inclusion Criteria:\n\n* Signed informed consent must be obtained prior to participation in the study.\n* Males or females ≥ 18 years of age\n* Within 14 days of a successful percutaneous coronary intervention (PCI) or peripheral endovascular intervention (PVI) for symptomatic CAD or lower extremity PAD\n* Patients undergoing planned staged interventions are eligible for randomization only after the last planned intervention\n\nExclusion Criteria:\n\n* Planned future PCI or PVI\n* Current or planned use of an open-label PCSK9 inhibitor during the study\n* Any prior treatment with inclisiran\n* Active or planned participation in another clinical study involving investigational drugs or devices during the study\n* Any serious liver disease, metabolic disease, neoplasm, end-stage kidney disease, or other condition in the opinion of the investigator that would inhibit trial participation or confound trial results\n* Any other reason why, in the opinion of the investigator, the participant would not be suitable for study participation including safety considerations and the ability to adhere to protocol activities\n* Patients taking prohibited therapies as listed in Section 6.6.3\n* Pregnant or breast-feeding women","ALL","18 Years",{"count":21,"type":22},6000,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.",[28,29],"Percutaneous Coronary Intervention","Peripheral Endovascular Intervention",[31,32,33,34,35,28,36],"inclisiran","Coronary Artery Disease","hypercholesterolemia","Cardiovascular Disease","Percutaneous Endovascular Intervention","PCSK9","RECRUITING","2026-07-10",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":41},"2025-07-23",{"date":45,"type":22},"2029-12",{"name":47,"class":48},"Duke University","OTHER",111,{"id":51,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":26,"conditions":54,"keywords":55,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":60,"leadSponsor":61,"locationsCount":62},"100585991",{"count":21,"type":22},[25],[28,29],[31,32,33,34,35,28,36],"2026-07-01",{"date":58,"type":41},"2026-07-02",{"date":43,"type":41},{"date":45,"type":22},{"name":47,"class":48},109,{"id":64,"slug":65,"hasResults":12,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":12,"sex":18,"minAge":71,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":23,"phases":74,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100394478","phase-4-potassium-competitive-acid-blocker-versus-proton-pump-inhibitor-for-gastroprotection-strategies-in-patients-at-high-gastro-intestinal-bleeding-risk-receiving-antithrombotic-therapy-100394478","NCT04416581","Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy","A Multi-centre, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Phase 4 Efficacy and Safety Study of P-CAB (Tegoprazan 50 mg Once Daily) Compared With PPI (Rabeprazole 20 mg Once Daily) to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease","PROTECT-HBR","Inclusion Criteria:\n\n1. Patients 19 years of age or older with known cardiac and vascular disease who are receiving chronic use of antithrombotic drugs (either antiplatelets, oral anticoagulant (OAC), and its combinations). Specific clinical conditions that may confer a need for long-term antithrombotic therapy may include documented coronary artery disease (stable or unstable angina, acute coronary syndrome, a history of myocardial infarction, or any coronary revascularization), documented cerebrovascular disease (stroke or transient ischemic attack), known peripheral arterial disease or a history of peripheral arterial revascularization, atrial fibrillation, or valvular heart disease requiring interventions (transcatheter aortic valve replacement or transcatheter mitral-valve repair). Concomitant use of a proton pump inhibitor is strongly recommended in patients receiving aspirin monotherapy, DAPT (dual antiplatelet therapy; aspirin plus any P2Y12 inhibitors), DAT (dual antithrombotic therapy; antiplatelet drug plus OAC), TAT (triple antithrombotic therapy; DAPT plus OAC), or OAC monotherapy (warfarin or direct oral anticoagulants) who are at high risk of GI bleeding in order to reduce the risk of gastric bleed or GI events. Based on clinical guidelines, the use of P2Y12 inhibitor monotherapy (i.e. clopidogrel, ticagrelor, or prasugrel) is not considered in trial enrollment.\n2. On the basis of clinical guidelines and expert consensus documents, we defined a study population with an increased risk of gastrointestinal bleeding if they had a least 1 or more criteria of the following characteristics. Eligible patients for randomization must meet at least 1 characteristic of these criteria:\n\n   \\*Definition of patients who are at high risk of gastrointestinal bleeding\n   1. Age ≥65 years\n   2. Concomitant use of OAC and any antiplatelet therapy (mono or DAPT) (i.e., DAT or TAT)\n   3. Long-term use of oral NSAIDs (non-steroidal anti-inflammatory drugs) or steroids or high-dose NSAID therapy even during a relatively short-term period.\n   4. History of prior GI bleeding events at any time\n   5. History of a previously complicated ulcer\n   6. History of peptic ulcer disease or a previously uncomplicated ulcer\n   7. Documented Helicobacter pylori infection\n3. Patients who voluntarily participated in the written agreement\n\nExclusion Criteria:\n\n1. Active bleeding at the time of inclusion or a history of hereditary or acquired hemostatic disorder\n2. Any clinical contraindication to using of antithrombotic therapies (antiplatelet agents or OAC)\n3. Concurrent use of PPI or P-CAB within 4 weeks before randomization\n4. Hemodynamically unstable conditions at the time of inclusion: cardiogenic shock at the time of randomization, refractory ventricular arrhythmias, or congestive heart failure (New York Heart Association class IV).\n5. Baseline severe anemia (Hgb \\\u003C8 g\u002Fdl at baseline) or transfusion within 4 weeks before randomization\n6. Baseline severe thrombocytopenia (platelet count \\\u003C50,000\u002Fmm3)\n7. Renal failure dependent on dialysis or severe renal insufficiency (creatinine clearance \\\u003C15 ml\u002Fmin)\n8. Severe chronic liver disease (defined as variceal haemorrhage, ascites, hepatic encephalopathy, or jaundice)\n9. Hypersensitivity or contraindication to PPI, P-CAB, any of the product components, or substituted benzimidazoles\n10. Use of clarithromycin and hypersensitivity to macrolide antibiotics for Helicobacter pylori eradication\n11. Concomitant use of clarithromycin with terfenadine, cisapride, astemizole, or pimozide for Helicobacter pylori eradication\n12. Systemic treatment with strong CYP 3A4 and p-glycoprotein (P-GP) inhibitors (e.g., systemic azole antimycotics, such as ketoconazole, and human immunodeficiency virus \\[HIV\\]-protease inhibitors, such as ritonavir)\n13. Patients who take atazanavir, nelfinavir, or rilpivirine-containing products (see Drug-Drug interaction section)\n14. Clinically significant laboratory abnormality at screening (estimated glomerular filtration rate (eGFR) \\\u003C15 mL\u002Fmin or elevated liver enzyme \\[AST, ALT, ALP, total bilirubin\\] \\> 3 times upper normal limit \\[UNL\\] or any other condition that, in the opinion of the Investigator, precludes participation in the study\n15. Any known or suspected malignancy\n16. Patients with non-cardiac co-morbidities with a life expectancy of less than 12 months\n17. Patients with active treatment for H-pylori infection\n18. Women who are pregnant or breastfeeding or female subjects, premenopausal who are not surgically sterile, or, if sexually active not practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; and, for those of childbearing potential, who have a positive pregnancy test at screening\n19. Participation in another clinical study within 12 months. However, where at least one or more conditions are satisfied, it could be an exception according to an investigator's discretion;\n\n    1. Participated in the observational study expected no effect on the safety and\u002For effectiveness evaluation of this trial\n    2. Screening failed before any interventional factor is involved\n    3. Participated in academic trials like strategic or medical device comparison studies conducted under standard therapy provided that there is no additional risk or a specific procedure to a subject and no interference between this trial and other studies","19 Years",{"count":73,"type":22},3320,[25],"The primary aim of this study is to evaluate the efficacy and safety of novel P-CAB (tegoprazan 50 mg once daily) as compared with standard PPI (rabeprazole 20 mg once daily) for protection of GI events in patients with known cardiac and vascular disease receiving chronic use of antithrombotic drugs (either antiplatelets, OAC, and its combinations) who are at high GI bleeding risk. The primary hypothesis is that P-CAB (experimental arm) would non-inferior to PPI (standard arm) with respect to the rate of the primary composite end point of GI events at 12 months after randomization.",[32,28,77,78],"Acute Coronary Syndrome","Myocardial Infarction",[80,81,82,83,84,85,86,87,88,89,90],"gastroduodenal ulcer","gastrointestinal hemorrhage","peptic ulcer","acute coronary syndrome","coronary artery stent placement","antiplatelet","anticoagulant therapy","PPI","P-CAB","Proton-pump inhibitors","Potassium-Competitive Acid Blockers","2026-06-24",{"date":93,"type":41},"2026-06-26",{"date":95,"type":41},"2021-05-12",{"date":97,"type":22},"2028-02-28",{"name":99,"class":48},"Duk-Woo Park, MD",45,{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100642956","coronary-thrombus-modification-to-prevent-microvascular-damage-in-patients-with-st-segment-elevation-myocardial-infarction-the-cormi-trial-100642956","NCT07646977","CORonary Thrombus Modification to Prevent MIcrovascular Damage in Patients With ST-segment Elevation Myocardial Infarction (The CORMI Trial)","Inclusion Criteria:\n\n* ST-elevation at the J-junction in a minimum of two contiguous ECG leads with a minimum of ≥ 0.1 mV in all leads, except for V2 and V3 (which required ≥ 0.2 for men ≥ 40 years old, ≥ 0.25 in men \\\u003C 40 years old, or ≥ 0.15 mV for all women) or new left bundle branch\n* Admission to hospital within 12 hours of symptom debut\n* Angiographic signs of a culprit lesion planned to be treated with primary percutaneous coronary intervention\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years or inability to provide informed consent\n* Life expectancy of \\\u003C 12 months\n* Hemodynamically instability\n* Pregnancy or breastfeeding\n* Known asthma or severe chronic obstructive pulmonary disease\n* Expected inability to perform physiological measurements (due to severely tortuous arteries, ostial disease or very distal disease),\n* CMR contraindications (estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin, magnetic or mechanically activated implants, or any prior metal implants, severe claustrophobia)\n* Expected to or unavoidable to use thrombectomy",{"count":108,"type":22},100,[110],"NA","The aim of this study is to evaluate the effects of coronary thrombus modification on preventing the microvascular damage associated with primary percutaneous coronary intervention (PCI), and to limit the associated myocardial damage assessed by myocardial salvage index after 3 months. Furthermore, the project will evaluate coronary microvascular damage assessed invasively using both continuous and bolus thermodilution before and after stent implantation. In addition, the project will evaluate the diagnostic ability and associations of pre-stenting invasive physiological measurement to cardiac magnetic resonance imaging measurements.",[113,114,28],"ST Elevation Myocardial Infarction","Coronary Microvascular Dysfunction",[116,117,118,119,120],"Microvascular damage","Continuous thermodilution","Bolus thermodilution","Myocardial damage","Cardiac MRI","NOT_YET_RECRUITING","2026-06-19",{"date":91,"type":41},{"date":125,"type":22},"2026-06",{"date":127,"type":22},"2034-01",{"name":129,"class":48},"Odense University Hospital",1,{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":139,"targetDuration":141,"studyType":142,"phases":4,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":158,"leadSponsor":160,"locationsCount":130},"100636249","polymer-free-sirolimus-eluting-stent-real-world-investigation-of-safety-and-outcomes-100636249","NCT07563231","Polymer-free Sirolimus Eluting Stent: Real-world Investigation of Safety and Outcomes","POLARIS : POLymer-free Sirolimus Eluting Stent: Real-world Investigation of Safety and Outcomes","POLARIS","Inclusion Criteria:\n\n* Age \\>= 18 years at the time of the index procedure.\n* Percutaneous coronary intervention performed at Geneva University Hospitals between January 2021 and December 2025.\n* Implantation of at least one study device\n* Indication for PCI according to current European or American guidelines.\n* Able and willing to provide written informed consent.\n* Sufficient knowledge of French, German, English, or Italian to understand the patient information document.\n\nExclusion Criteria:\n\n* Documented refusal to participate in research through opt-out from general consent.\n* Inability to provide informed consent (cognitive impairment or other).\n* Inability to be contacted for informed consent (no valid contact information, or unreachable after three contact attempts).\n* Life expectancy less than 12 months due to non-cardiac comorbidities at the time of consent.\n* Participation in another clinical trial that would interfere with the endpoints of this registry.",{"count":140,"type":22},300,"5 Years","OBSERVATIONAL","POLARIS is a prospective, single-centre, single-arm observational pilot registry evaluating the real-world safety and efficacy of the Focus np (Abluminus np, Concept Medical, Tampa, FL, USA) polymer-free sirolimus-eluting stent in consecutive adult patients undergoing percutaneous coronary intervention (PCI). The primary endpoint is target lesion failure (TLF) at 12 months, defined per Academic Research Consortium-2 (ARC-2) criteria as the device-oriented composite of cardiac death, target vessel myocardial infarction, and clinically indicated target lesion revascularisation. Patients treated since January 2021 will be retrospectively identified and prospectively consented, with follow-up through 5 years. The registry will provide the first Western clinical evidence on this CE-marked device and serve as a template for a future national Swiss multicentre registry.",[32,77,78,145,28],"Stent Thrombosis",[147,148,149,150,151,152,153],"drug-eluting stent","polymer-free stent","sirolimus","percutaneous coronary intervention","target lesion failure","registry","real-world evidence","2026-06-05",{"date":156,"type":41},"2026-06-09",{"date":125,"type":22},{"date":159,"type":22},"2036-06",{"name":161,"class":48},"Dorian Garin",{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":12,"sex":18,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":4},"100638489","effects-of-diaphragmatic-and-abdominal-neuromuscular-electrical-stimulation-in-post-pci-patients-100638489","NCT07629037","Effects of Diaphragmatic and Abdominal Neuromuscular Electrical Stimulation in Post-PCI Patients","Effects of Diaphragmatic and Abdominal Neuromuscular Electrical Stimulation on Arterial Blood Gases, Pulmonary Function, Ejection Fraction and Functional Capacity in Post-PCI Patients","Inclusion Criteria:\n\n* Patients aged 40-75 years\n* Patients who have undergone successful percutaneous coronary intervention (PCI) for stable or acute coronary syndrome\n* Hemodynamically stable (no inotropic support, no active arrhythmias)\n* Left ventricular ejection fraction (LVEF) ≥ 35%\n* Able to perform spirometry and 6-minute walk test (6MWT)\n* Willing to participate and provide informed consent\n\nExclusion Criteria:\n\n* Significant arrhythmias or pacemaker\u002Fimplantable defibrillator not cleared for NMES\n* Severe pulmonary disease (e.g., advanced COPD, pulmonary fibrosis) affecting lung function independently\n* Neuromuscular disorders interfering with NMES application\n* Recent stroke or severe cognitive impairment limiting participation\n* Active infection, sepsis, or systemic inflammatory disease","40 Years","75 Years",{"count":172,"type":22},42,[110],"This study is a randomized controlled trial designed to evaluate the effects of combined diaphragmatic and abdominal neuromuscular electrical stimulation (NMES) on arterial blood gases, pulmonary function, left ventricular ejection fraction, and functional capacity in patients following percutaneous coronary intervention (PCI). A total of 42 participants will be randomly allocated into two groups: an intervention group receiving NMES along with standard cardiac rehabilitation, and a control group receiving standard rehabilitation alone. The intervention will be administered for 30 minutes per session, five days per week, over a period of two weeks. Outcome measures will include arterial blood gas parameters (PaO₂, PaCO₂, SaO₂), spirometry indices (FVC, FEV₁, PEFR), ejection fraction assessed by echocardiography, and functional capacity measured using the 6-minute walk test. Assessments will be conducted at baseline and post-intervention. The study aims to determine whether NMES can serve as an effective adjunct to conventional cardiac rehabilitation in improving respiratory and functional outcomes in post-PCI patients.",[28],[177],"Cardiac Rehab Coronary Stent","2026-06-01",{"date":154,"type":41},{"date":181,"type":22},"2026-05-28",{"date":183,"type":22},"2026-06-29",{"name":185,"class":48},"Riphah International University",{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":23,"phases":195,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":203,"leadSponsor":205,"locationsCount":4},"100638823","phase-3-clinical-study-of-chinese-herbal-compound-qidan-xiaoke-granules-in-patients-after-coronary-revascularization-100638823","NCT07616544","Clinical Study of Chinese Herbal Compound Qidan Xiaoke Granules in Patients After Coronary Revascularization","Inclusion Criteria:\n\n1. Age: 18-80 years old;\n2. no gender limitation;\n3. Meets the diagnostic criteria for coronary heart disease;\n4. Accepts effective PCI procedure;\n5. Voluntarily participates and signs a written informed consent form.\n\nExclusion Criteria:\n\n1. Severe hepatic and\u002For renal insufficiency\n2. Severe electrolyte disorders\n3. Severe hematological diseases or malignant tumors\n4. Pregnant or breastfeeding women\n5. Patients with mental illness\n6. Cognitive impairment (e.g., dementia, post-stroke cognitive impairment) leading to inability to communicate normally\n7. Planning to undergo another revascularization surgery in the near future\n8. Other severe cardiovascular diseases (e.g., uncontrolled hypertension, angina pectoris, rapid arrhythmias, high-degree or complete atrioventricular block without a pacemaker implanted, acute severe aortic stenosis, decompensated heart failure (NYHA Class IV), deep vein thrombosis, obstructive hypertrophic cardiomyopathy, acute pericarditis or myocarditis, acute endocarditis, acute aortic dissection, etc.)\n9. Acute pulmonary embolism and chronic lung diseases with dyspnea symptoms (occurring at rest or with minimal exertion)\n10. Explicit exclusion criteria (bleeding history within 1 month, active bleeding, bleeding tendency, currently using anticoagulants)\n11. Participants in other interventional clinical trials within the past month\n12. Allergy to known components of the investigational drug (Qidan Xiaohe Granules)\n13. Other conditions deemed unsuitable for participation in the trial by the investigator","80 Years",{"count":194,"type":22},164,[196],"PHASE3","1. Evaluate the efficacy and safety of Qidan Xiaohe granules in patients after coronary revascularization surgery;\n2. Develop a traditional Chinese medicine rehabilitation treatment plan and evaluation system for the use of Qidan Xiaohe granules after coronary revascularization surgery;\n3. Demonstrate the advantages of traditional Chinese medicine rehabilitation treatment in the postoperative management of coronary revascularization surgery and provide high-level evidence-based medical evidence for the development of traditional Chinese medicine rehabilitation treatment plans.",[28,199,32],"Myocardial Revascularization","2026-05-27",{"date":178,"type":41},{"date":56,"type":22},{"date":204,"type":22},"2028-12-31",{"name":206,"class":48},"Liu Qiang",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":23,"phases":216,"briefSummary":217,"conditions":218,"keywords":223,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":130},"100584513","timing-of-anticoagulant-administration-during-radial-access-percutaneous-coronary-intervention-the-hera-pci-study-heparin-early-for-radial-access-percutaneous-coronary-intervention-100584513","NCT06890312","Timing of Anticoagulant Administration During Radial Access Percutaneous Coronary Intervention: the HERA-PCI Study (Heparin Early for Radial Access Percutaneous Coronary Intervention)","HERA-PCI","Inclusion Criteria:\n\n* Patients having 18 years old or older, regardless of gender, undergoing percutaneous radial coronary intervention\n* Subject affiliated to a social protection health insurance\n* Subject able to understand the objectives and risks of the research and to provide dated and signed consent\n* Subject who has been informed of the results of the preliminary medical examination\n\nExclusion Criteria:\n\n* Contraindication to the use of heparin (history of heparin-induced thrombocytopenia)\n* Very high bleeding risk defined by recent bleeding (\\\u003C6 months) of type 3 of the BARC classification\n* Subject in an exclusion period (determined by a previous or ongoing study)\n* Inability to give the subject enlightened information (subject in an emergency situation, difficulties in understanding the subject, etc.)\n* Subject under safeguard of justice\n* Subject under guardianship or curatorship\n* Pregnancy\n* Breastfeeding\n* Patient on anticoagulant treatment: anti-vitamin K, direct oral anticoagulants (DOACs).",{"count":215,"type":22},550,[110],"While the reduced hemorrhagic risk of radial access for percutaneous coronary intervention compared to femoral access is well-established, its main complication remains radial artery occlusion, which can occur in up to 30% of patients. Anticoagulation is the primary preventive measure recommended in clinical practice to reduce the risk of this complication, typically involving heparin injection during the procedure in most centers. However, data on the effect of the timing of heparin injection are limited. The investigators hypothesize that injection of heparin before sheath insertion may reduce the rate of radial artery occlusion compared with injection after sheath insertion.",[219,28,220,221,222],"Coronary Angiography","Radial Artery Occlusion","Bleeding","Anticoagulation",[224,225,226,227,228],"Anticoagulant injection timing","Percutaneous coronary intervention","Coronary angiography","Radial artery occlusion prevention","Bleeding events","2026-05-20",{"date":231,"type":41},"2026-05-26",{"date":233,"type":41},"2025-06-05",{"date":235,"type":22},"2028-01",{"name":237,"class":48},"University Hospital, Strasbourg, France",{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":192,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":252,"leadSponsor":253,"locationsCount":4},"100639118","baduanjin-intervention-in-clinical-studies-after-coronary-revascularization-surgery-100639118","NCT07607951","Baduanjin Intervention in Clinical Studies After Coronary Revascularization Surgery","Inclusion Criteria:\n\n* Participants who meet the diagnostic criteria for coronary heart disease\n* Participants who underwent successful percutaneous coronary intervention\n* Participants aged between 18 and 80\n* Participants of any gender\n* Participants who have signed an informed consent form\n\nExclusion Criteria:\n\n* Subjects with severe hepatic or renal impairment\n* subjects with severe electrolyte disturbances\n* subjects with severe haematological disorders or malignant tumours\n* pregnant or breastfeeding women\n* subjects with psychiatric disorders\n* subjects with cognitive impairment (e.g. dementia, post-stroke cognitive impairment) that prevents them from understanding or carrying out exercise instructions\n* Subjects scheduled to undergo repeat revascularisation surgery in the near future\n* Subjects with other severe cardiovascular diseases such as uncontrolled hypertension, angina pectoris, rapid arrhythmias, high-degree or complete atrioventricular block (without a pacemaker), acute severe aortic stenosis, decompensated heart failure (NYHA Class IV), deep vein thrombosis, obstructive hypertrophic cardiomyopathy, acute pericarditis or myocarditis, acute endocarditis, or acute aortic dissection\n* Participants with acute pulmonary embolism or chronic lung disease accompanied by symptoms of dyspnoea (occurring at rest or with minimal exertion)\n* Subjects with impaired limb mobility or who are unable to move independently;\n* Subjects with Shy-Drager syndrome\n* Subjects who have participated in a clinical trial involving other drugs or exercise interventions within the past month\n* Subjects deemed by the investigator to have other conditions rendering them unsuitable for participation in the trial",{"count":245,"type":22},310,[110],"1. To evaluate the efficacy and safety of the Baduanjin exercise programme in patients following coronary revascularisation surgery;\n2. To develop a traditional Chinese medicine (TCM) rehabilitation protocol and evaluation system for patients following coronary revascularisation surgery;\n3. To clarify the advantages of TCM rehabilitation in the post-operative management of coronary revascularisation surgery and to provide high-level evidence-based medical evidence for TCM rehabilitation protocols.",[28,199,32],"2026-05-19",{"date":200,"type":41},{"date":56,"type":22},{"date":204,"type":22},{"name":206,"class":48},{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":130},"100637997","cardiac-rehab-referral-nudges-100637997","NCT07607522","Cardiac Rehab Referral Nudges","Inclusion Criteria:\n\n* Age of at least 18 years\n* History of Coronary Artery Bypass Grafting (CABG), Percutaneous Coronary Intervention (PCI), or valve repair\u002Freplacement in the past year\n\nExclusion Criteria:\n\n* Hospice\n* Active home health",{"count":261,"type":22},7000,"Investigators will evaluate the effectiveness of two different EHR-embedded nudges to improve referral to cardiac rehabilitation.",[28,264,265],"Valve Repair\u002FReplacement","Coronary Artery Bypass Grafting",{"date":231,"type":41},{"date":268,"type":22},"2026-06-15",{"date":270,"type":22},"2026-12-15",{"name":272,"class":48},"NYU Langone Health",{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":192,"enrollmentInfo":281,"targetDuration":4,"studyType":23,"phases":283,"briefSummary":284,"conditions":285,"keywords":291,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":297,"leadSponsor":299,"locationsCount":4},"100637529","computed-tomography-angiography-based-procedural-planning-in-percutaneous-coronary-intervention-100637529","NCT07592312","Computed Tomography Angiography Based Procedural Planning in PeRcutaneOus Coronary InterVEntion","CT-PROVE: Computed Tomography Angiography Based Procedural Planning in PeRcutaneOus Coronary InterVEntion","CT-PROVE","Inclusion Criteria:\n\n* Adults aged 18 to 80 years\n* Ability to provide written informed consent\n* Patients undergoing coronary computed tomography angiography (CCTA) for suspected coronary artery disease or for diagnostic work-up of stabilized acute coronary syndrome\n* Presence of at least one target coronary lesion meeting one of the following CCTA criteria:\n\n  * Severe coronary diameter stenosis (70-99%) in one or more coronary arteries according to CAD-RADS 4A or 4B classification and at least one of the following:\n  * CT-derived fractional flow reserve (CT-FFR) ≤0.80\n  * At least 2 high-risk plaque characteristics, including:\n  * Low attenuation plaque density \\\u003C30 Hounsfield units\n  * Positive remodeling index \\>1.1\n  * Napkin-ring sign\n  * Spotty calcification\n  * Left main coronary artery stenosis ≥50%\n  * Ostial or proximal left anterior descending artery, dominant left circumflex artery, or dominant right coronary artery stenosis ≥50% and at least one of the following:\n  * CT-FFR ≤0.80\n  * At least 2 high-risk plaque characteristics, including:\n  * Low attenuation plaque density \\\u003C30 Hounsfield units\n  * Positive remodeling index \\>1.1\n  * Napkin-ring sign\n  * Spotty calcification\n* Planned clinically indicated invasive coronary angiography with operator decision to proceed with PCI\n\nExclusion Criteria:\n\n* Contraindication to iodinated contrast media, including severe allergy or contrast-induced nephropathy\n* Poor-quality or non-diagnostic CCTA imaging\n* Target lesions involving in-stent restenosis\n* Chronic total occlusion target lesions\n* Operator decision to treat a vessel not identified as a target vessel by the CCTA core laboratory analysis\n* Pregnancy or breastfeeding\n* Patients referred for coronary artery bypass graft surgery after invasive coronary angiography\n* Participation in another investigational drug or drug-coated device study\n* Inability to provide informed consent",{"count":282,"type":22},200,[110],"The goal of this clinical trial is to learn whether coronary CT angiography (CCTA)-guided planning improves the efficiency and outcomes of percutaneous coronary intervention (PCI) in adults with coronary artery disease. It will also evaluate the feasibility and safety of using a CT-based \"virtual PCI plan\" during coronary interventions.\n\nThe main questions it aims to answer are:\n\n* Does CCTA-guided PCI reduce procedural time, radiation exposure, and contrast dye use compared with standard PCI?\n* Does CCTA-guided PCI improve procedural outcomes and stent optimization?\n* How often do operators follow or deviate from the CT-based procedural plan?\n* What medical problems or complications occur during and after CCTA-guided PCI?\n\nResearchers will compare CCTA-guided PCI with standard angiography-guided PCI to determine whether CT-derived procedural planning improves PCI efficiency and clinical outcomes.\n\nParticipants will:\n\n* Undergo PCI guided either by a CCTA-based virtual planning strategy or by standard clinical practice\n* Attend follow-up assessments at 1 month, 6 months, and 1 year\n* Undergo routine clinical evaluations and imaging assessments related to their PCI procedure\n* Be monitored for procedural complications, symptoms, repeat procedures, and cardiovascular outcomes during follow-up\n\nThe study will also include a parallel observational registry for patients whose coronary lesions are deferred from PCI, to evaluate their long-term clinical outcomes.",[286,287,288,289,28,290],"Coronary Arteries Disease","Chronic Coronary Syndrome","Acute Coronary Syndromes (ACS)","Myocardial Ischemia","Coronary Computed Tomography Angiography",[32,292,28,290],"Chronic Coronary Disease","2026-05-13",{"date":295,"type":41},"2026-05-18",{"date":295,"type":22},{"date":298,"type":22},"2028-12-30",{"name":300,"class":48},"University of Galway",{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":311,"briefSummary":312,"conditions":313,"keywords":318,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":130},"100638421","phase-3-study-of-the-long-term-effects-of-p2y12-inhibitor-monotherapy-and-coagulation-markers-after-percutaneous-coronary-angioplasty-100638421","NCT07582835","Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.","Hunting for the Long-Term EffeCts of P2Y12 Inhibitor monotHerapy and Coagulation Monitoring After PCI: an Open-label, Randomized Study.","HI-TECH 2","Inclusion Criteria:\n\n* Age ≥18 years\n* Prior (≥3 months) ACS and\u002For PCI\n* Eligible for P2Y12 inhibitor monotherapy after an uneventful DAPT course\n* Free from ischemic (i.e. any new episode of ACS, symptomatic restenosis, stent thrombosis, stroke, any revascularization requiring prolonged DAPT) and\u002For bleeding events (defined as BARC ≥ 2) for at least 3 months\n* Written informed consent.\n\nExclusion Criteria:\n\n* Unconscious patients\n* Unable to provide written informed consent\n* Under judicial protection, tutorship or curatorship\n* Unable to understand and follow study-related instructions or unable to comply with study protocol\n* Known hypersensitivity or allergy to clopidogrel, ticagrelor or prasugrel\n* Severe hepatic impairment\n* Haemoglobin level \\\u003C10 g\u002FdL or platelet count \\\u003C100 000 cells\u002FmL\n* Pregnant or breastfeeding women\n* Life expectancy less than 1 year\n* Active participation in another interventional trial\n* Need for concomitant oral anticoagulation\n* History of intracranial haemorrhage (anytime), transient ischemic attack or stroke within 3 months\n* PCI for in-stent restenosis or stent thrombosis at index PCI or within 6 months before randomization",{"count":310,"type":22},355,[196],"Patients who undergo percutaneous coronary intervention (PCI) are commonly treated with antiplatelet therapy to prevent stent thrombosis and recurrence of events. After an initial period of dual antiplatelet therapy, long-term treatment with a single P2Y12 inhibitor (such as clopidogrel, ticagrelor, or prasugrel) is often prescribed. However, the optimal drug and dose for long-term monotherapy remain uncertain, as patients may experience either insufficient platelet inhibition (leading to ischemic events) or excessive inhibition (increasing bleeding risk).\n\nThe HI-TECH 2 study aims to identify the most appropriate type and dose of P2Y12 inhibitor monotherapy to achieve a balanced level of platelet inhibition within a predefined therapeutic range. The study also seeks to better understand how blood coagulation activity evolves over time after PCI.\n\nThis is a prospective, investigator-initiated, single-center, open-label study conducted in two phases. In Phase 1, patients receive stepwise reduced doses of ticagrelor or prasugrel to determine the optimal dose that most consistently achieves the desired level of platelet inhibition. In Phase 2, patients are randomly assigned to receive clopidogrel or the optimal doses of ticagrelor or prasugrel identified in Phase 1.\n\nThe main question of the study is whether optimized ticagrelor or prasugrel regimens are more effective than standard-dose clopidogrel in achieving platelet inhibition within the target therapeutic window, as measured by validated platelet function tests. Additional objectives include evaluating the role of genetic factors in treatment response and assessing markers of coagulation activation over time.\n\nThe results of this study may help personalize long-term antiplatelet therapy after PCI, improving the balance between reducing thrombotic risk and minimizing bleeding complications.",[32,28,314,315,316,317],"Acute Coronary Syndromes","Antiplatelet Therapy","Single Antiplatelet Therapy","Coagulation Factors",[32,316,319,320,321,322,323,324,325,326,327,314,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343],"Antiplatelet therapy","Ticagrelor","Prasugrel","Coagulation biomarkers","Clopidogrel","Multiplate","VerifyNow","CYP2C19","ABCB1 gene","Dose optimization","platelet function tests (PFT)","Percutaneous Coronary Intervention (PCI)","High platelet reactivity (HPR)","Low platelet reactivity (LPR)","Bleeding Risk","Ischemic risk","prothrombin fragment F1+2","thrombin-antithrombin (TAT) complex","fibrinopeptide A","fibrinogen","D-dimer","von Willebrand factor activity (VWF)","plasminogen activator inhibitor-1 (PAI-1)","thrombin-activatable fibrinolysis inhibitor (TAFI)","circulating extracellular vesicles","2026-05-06",{"date":293,"type":41},{"date":347,"type":22},"2026-04-20",{"date":349,"type":22},"2028-04",{"name":351,"class":48},"Cardiocentro Ticino",{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":359,"targetDuration":141,"studyType":142,"phases":4,"briefSummary":361,"conditions":362,"keywords":369,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":130},"100636493","overviewing-real-world-outcomes-to-boost-interventional-management-of-calcified-coronary-lesions-the-orobica-registry-100636493","NCT07566403","Overviewing Real-World Outcomes to Boost Interventional Management of CAlcified Coronary Lesions: the OROBICA Registry.","OROBICA","Inclusion Criteria:\n\n* Patients undergoing percutaneous coronary intervention (PCI) for severely calcified coronary lesions, angiographically defined as radiopacities noted without cardiac motion before contrast injection, generally involving both sides of the arterial wall.\n* Patients undergoing PCI for calcified coronary lesions with intracoronary optical coherence tomography (OCT) showing at least one of the following features:\n\n  * calcium arc ≥180°\n  * calcium thickness ≥0.3 mm\n  * calcium length ≥3 mm\n  * presence of calcified nodules\n* Patients undergoing PCI for calcified coronary lesions with intravascular ultrasound (IVUS) showing at least one of the following features:\n\n  * calcium arc ≥180°\n  * concentric or superficial calcium with extensive acoustic shadowing\n  * presence of calcified nodules\n\nExclusion Criteria:\n\n* Lack of availability of essential clinical or procedural data.\n* Refusal or withdrawal of informed consent for the prospective component of the registry, when applicable.\n* Exercise of the right to object to data processing, according to applicable data protection regulations.",{"count":360,"type":22},3000,"The OROBICA (Overviewing Real-World Outcomes to Boost Interventional Management of CAlcified Coronary Lesions) Registry is a multicenter, ambispective, real-world observational study designed to evaluate clinical, procedural, imaging, and economic outcomes of patients undergoing percutaneous coronary intervention (PCI) for severely calcified coronary artery disease.\n\nCoronary artery calcification represents one of the main determinants of procedural complexity and adverse outcomes in contemporary interventional cardiology. Despite the increasing availability of advanced calcium-modification technologies and intracoronary imaging techniques, evidence regarding the optimal treatment strategy in real-world clinical practice remains limited, particularly among high-risk and complex patients often underrepresented in randomized trials.\n\nThe OROBICA Registry aims to systematically collect longitudinal data from all-comer patients treated for severely calcified coronary lesions using contemporary PCI strategies, including intracoronary imaging guidance (IVUS\u002FOCT), rotational atherectomy, orbital atherectomy, intravascular lithotripsy, specialty balloons, and combined calcium-modification approaches.\n\nThe primary objective is to assess clinical and procedural outcomes, with particular focus on target vessel failure (TVF). Secondary and exploratory objectives include evaluation of procedural success, imaging findings, predictors of adverse outcomes, healthcare resource utilization, and economic impact associated with the treatment of calcified coronary lesions.\n\nThe registry is designed as a flexible research platform intended to support future hypothesis-generating analyses and provide real-world evidence to improve personalized management strategies for calcified coronary artery disease.",[363,364,365,366,367,368,28],"Coronary Artery Disease (CAD)","Calcific Coronary Arteriosclerosis","Intravascular Lithotripsy; Rotational Atherectomy; OFDI","Orbital Atherectomy","Optical Coherence Tomography (OCT)","Intravascular Ultrasound",[370,371,150,372,373,374,375,376,377,378],"Coronary calcifications","coronary artery disease","intravascular imaging","atherectomy","intravascular lithotripsy","rotational atherectomy","orbital atherectomy","cutting balloon","target vessel failure","2026-05-04",{"date":344,"type":41},{"date":382,"type":22},"2026-06-30",{"date":384,"type":22},"2036-06-30",{"name":386,"class":48},"Papa Giovanni XXIII Hospital",{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":23,"phases":395,"briefSummary":396,"conditions":397,"keywords":402,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":412,"locationsCount":130},"100560360","ultrasound-guided-transversus-abdominis-plan-tap-block-in-endovascular-cardiac-interventions-100560360","NCT06576128","Ultrasound-Guided Transversus Abdominis Plan (TAP) Block in Endovascular Cardiac Interventions","Analgesic Effect of Ultrasound-Guided Transversus Abdominis Plan (TAP) Block in Femoral Endovascular Cardiac Interventions: A Prospective-randomized Study","Inclusion Criteria:\n\n* The patient is over 18 years of age\n* Coronary angiography, cardiac catheterization and percutaneous coronary intervention will be applied to the patient,\n* The above-mentioned procedures will be taken under elective conditions,\n* Providing an optimal image when imaging the patient with ultrasound,\n* INR\\\u003C 1.5\n* If the patient gives consent, S\u002Fhe will be included in the study.\n\nExclusion Criteria:\n\n* Patients under 18 years of age,\n* Patients treated under emergency conditions,\n* morbid obesity (BMI\\>35 kg\u002Fm2),\n* pregnant women,\n* New York Heart Association (NYHA) stage 4 patients with advanced decompensated heart failure,\n* Patients with symptoms such as redness, temperature increase, infection, hematoma in the application area before the procedure,\n* Patients with a history of allergy to local anesthetics,\n* Patients who cannot be communicated,\n* Those with severe psychosis or progressive neurological deficits and muscle disease,\n* Patients who do not consent to the application will be excluded from the study.",{"count":108,"type":22},[110],"Sensory innervation of the femoral region which is the entry point for endovascular cardiac interventions such as coronary angiography,cardiac catheterization and percutaneous coronary intervention is complex.It is thought that the ilioinguinal and iliohypogastric nerves contribute mostly.With transversus abdominis plane block(TAPB),it is planned to provide analgesia by creating a block in these nerve branches that contribute to the sensory innervation of the intervention area.In addition;it was aimed to investigate patient's and physician's satisfaction during the procedure.",[398,28,399,400,401],"Anesthesiology","Cardiac Catheterization","Analgesia","Satisfaction, Patient",[403,404,405,28,399,406],"ultrasonography","anesthesiology","transversus abdominis plane block","analgesia",{"date":408,"type":41},"2026-05-08",{"date":410,"type":41},"2024-09-10",{"date":270,"type":22},{"name":413,"class":48},"Istanbul University - Cerrahpasa",{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":18,"minAge":422,"maxAge":4,"enrollmentInfo":423,"targetDuration":4,"studyType":23,"phases":425,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":4},"100634410","clinical-impact-of-dcb-based-versus-des-based-intervention-in-patients-with-mvcad-100634410","NCT07539324","Clinical Impact of DCB-based Versus DES-based Intervention in Patients With MVCAD","Clinical Impact of Drug-Coated-Balloon-based Versus Drug-Eluting-Stent-based Intervention in Patients With Multivessel Coronary Artery Disease : A Prospective, Multicenter, Active-controlled, Randomized, Single-blind, Investigator-initiated Clinical Trial","DCBMultivessel","Inclusion Criteria:\n\n1. Male or female adults aged 20 years or older with stable angina, silent myocardial ischemia, unstable angina, or non-ST-segment elevation myocardial infarction (NSTEMI).\n2. In cases of ST-segment elevation myocardial infarction (STEMI), patients who have undergone successful primary percutaneous coronary intervention (PCI) without complications, at least 48 hours post-procedure, and whose target lesion(s) show no evidence of thrombus.\n3. Patients with multivessel coronary artery disease, defined as angiographic stenosis of 50% in at least two major epicardial coronary arteries requiring PCI as determined by the investigator.\n4. Reference vessel diameter (RVD) of the target lesion(s) between 2.25 mm and 4.0 mm by visual estimation or quantitative coronary angiography (QCA).\n5. Target lesions suitable for treatment with either drug-eluting stents (DES) or drug-coated balloons (DCB).\n6. Patients who have voluntarily provided written informed consent and are willing and able to comply with all protocol-specified requirements.\n\nExclusion Criteria:\n\n1. Cardiogenic shock or patients requiring mechanical or pharmacological circulatory support.\n2. Patients with a life expectancy of less than 2 years due to comorbid conditions.\n3. Patients who are currently participating or planning to participate in other interventional clinical trials, excluding observational studies.\n4. Women who are pregnant or have childbearing potential.\n5. Patients with a known hypersensitivity or allergy to contrast media, L-605 Cobalt-Chromium (Co-Cr) alloy, PLA and PLGA polymers, shellac, Vitamin E-TPGS, paclitaxel, or sirolimus.\n6. Patients with a target lesion located within a saphenous vein graft (SVG) or an arterial graft.\n7. Patients with target vessels\u002Flesions that are excessively tortuous, angulated, or severely calcified, such that pre-dilatation cannot be performed or has failed, making the application of the investigational medical device difficult.","20 Years",{"count":424,"type":22},892,[110],"This study aimes to compare the clinical outcomes of drug-coated balloon-based percutaneous coronary intervention (DCB-based PCI) and drug-eluting stent-based percutaneous coronary intervention (DES-based PCI) in patients with multivessel coronary artery lesions measuring 2.25 mm to 4.0 mm in diameter through a prospective, multicenter, active-controlled, randomized, investigator-initiated clinical trial.",[428,28],"Multi Vessel Coronary Artery Disease","2026-04-13",{"date":347,"type":41},{"date":432,"type":22},"2026-04-15",{"date":434,"type":22},"2032-07-31",{"name":436,"class":437},"Genoss Co., Ltd.","INDUSTRY",{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":18,"minAge":422,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":446,"conditions":447,"keywords":451,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":130},"100629034","preliminary-exploration-of-factors-affecting-complete-hemostasis-and-supine-time-after-removal-of-femoral-arterial-sheath-in-icu-patients-100629034","NCT07469397","Preliminary Exploration of Factors Affecting Complete Hemostasis and Supine Time After Removal of Femoral Arterial Sheath in ICU Patients","Inclusion Criteria:\n\n1. Patients admitted to the cardiac intensive care unit of this hospital.\n2. Patients undergoing femoral arterial sheath removal.\n3. Age 20 years or older.\n\nExclusion Criteria:\n\n1. Patients unable to maintain supine position or refusing physical restraints.\n2. Patients with severe hematoma, vascular rupture, or other vascular complications present at the femoral arterial puncture site at the time of sheath insertion.\n3. Patients with a diagnosis of severe disseminated intravascular coagulation (DIC).",{"count":445,"type":22},157,"Background:Following cardiac catheterization and arterial sheath removal, manual compression is applied until bleeding stops, after which a compression belt is used. Patients must lie supine for at least 6 hours, often experiencing discomfort including back pain, eating difficulties, and urinary problems. The compressed leg is restrained to prevent movement, adding to the discomfort. Despite adhering to this standard procedure, some patients still develop bleeding or hematomas after compression, requiring extended treatment. Current research on predicting compression duration and bleeding risk factors after femoral arterial sheath removal is limited and inconsistent. This study aims to identify factors that can more accurately predict necessary compression time after initial hemostasis, potentially reducing patient discomfort and complications such as prolonged bleeding, extended compression, and hematoma formation, which can impact vital signs.\n\nPurpose:To understand the factors influencing complete hemostasis and supine duration after femoral arterial sheath removal in ICU patients.\n\nMethods:Clinical data were collected through observation, and statistical analysis was performed using SPSS.\n\nExpected Outcomes:To identify factors that influence complete hemostasis and supine duration after femoral arterial sheath removal in ICU patients, and to develop a prediction model that allows clinical units to accurately assess the required supine compression time following femoral arterial sheath removal.",[448,449,32,28,450],"Removal of Femoral Arterial Sheath in ICU Patients","Complete Hemostasis","Transcatheter Aortic Valve Implantation (TAVI)",[449,452],"Supine Time","2026-03-10",{"date":455,"type":41},"2026-03-13",{"date":457,"type":41},"2025-05-15",{"date":459,"type":22},"2026-12-31",{"name":461,"class":48},"National Taiwan University Hospital",{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":470,"targetDuration":4,"studyType":23,"phases":472,"briefSummary":473,"conditions":474,"keywords":477,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":486,"locationsCount":130},"100627237","ivus-ffr-accuracy-for-coronary-stenosis-100627237","NCT07446023","IVUS-FFR Accuracy for Coronary Stenosis","Diagnostic Accuracy of Intravascular Ultrasound-Derived Fractional Flow Reserve for Online Assessment of Functionally Significant Coronary Stenosis: A Multicenter Prospective Study","IVUS-FFR","Inclusion Criteria General Requirements\n\n* 18 years of age Diagnosed with stable\u002Funstable angina or post-acute phase myocardial infarction (\\>72 hours after onset) Able to comprehend study design and provide written informed consent Angiographic \\& IVUS-Specific Requirements\n* 1 epicardial coronary artery with 30%-90% visual diameter stenosis Reference vessel diameter ≥2.0 mm at target stenosis site Exclusion Criteria General Exclusions Contraindications to invasive procedures\u002FFFR per operator judgment Acute myocardial infarction within 72 hours Cardiogenic shock or severe heart failure (NYHA class ≥III or LVEF \\\u003C30%) Severe renal dysfunction (Creatinine \\>150 μmol\u002FL or eGFR \\\u003C45 mL\u002Fmin\u002F1.73m²) Allergy to iodinated contrast media or adenosine Pregnancy\u002Flactation Life expectancy \\\u003C1 year Concurrent participation in other interventional trials Angiographic \\& IVUS-Specific Exclusions Myocardial bridging at target lesion Severely calcified or tortuous vessels precluding safe IVUS Isolated \\>90% stenosis with TIMI flow grade \\\u003C3 in major epicardial artery Other conditions deemed unsuitable for IVUS\u002FFFR by investigators",{"count":471,"type":22},292,[110],"IVUS-FFR Online Accuracy for Coronary Stenosis What is this study testing? This study is testing a new technology called IVUS-FFR , which uses ultrasound imaging inside heart arteries (IVUS) to quickly measure whether a narrowed artery ( coronary stenosis ) is reducing blood flow. Unlike the current standard test (FFR), this new method doesn't require extra wires or medication to work.\n\nWhy is this important?\n\nMany patients with heart artery narrowing need tests to decide if a stent is necessary.\n\nCurrent FFR tests involve inserting a pressure wire and giving medication (like adenosine) that can cause discomfort.\n\nIVUS-FFR could provide equally accurate results faster, cheaper, and more comfortably .\n\nWhat happens in the study?\n\nIf you join:\n\nStandard heart artery imaging (angiogram) will be performed. An ultrasound probe (IVUS) will be moved through the artery to create detailed images.\n\nThe new IVUS-FFR software will analyze these images immediately to estimate blood flow.\n\nFor comparison, a standard FFR test (with pressure wire and medication) will also be done.\n\nAll steps use existing approved devices and take \\\u003C10 extra minutes. Who can participate?\n\nAdults (≥18 years) with:\n\nSuspected or known heart artery disease At least one artery narrowing (30%-90% blocked) Excluded: Recent heart attack (\\\u003C72 hrs), severe kidney\u002Fheart failure, or pregnancy.\n\nWhat are the risks and benefits?\n\nRisks: Same as routine heart catheterization (bleeding, infection, artery injury). The IVUS and FFR steps add minimal extra risk.\n\nBenefits: No direct benefit, but results may improve future care by reducing need for invasive tests.\n\nStudy goal:\n\nTo validate if IVUS-FFR is as accurate as the current FFR standard in 292 patients across multiple hospitals in China.\n\nWho is running the study? Led by heart specialists at Fuwai Hospital (Beijing) - China's top cardiovascular center - with ethics committee oversight.",[28,475,476],"Intravenous Ultrasound","Coronary Physiology",[28,475,476,478,468,479],"Fractional Flow Reserve","Diagnostic Accuracy","2026-02-25",{"date":482,"type":41},"2026-03-03",{"date":484,"type":41},"2025-07-01",{"date":459,"type":22},{"name":487,"class":488},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":18,"minAge":71,"maxAge":4,"enrollmentInfo":495,"targetDuration":4,"studyType":23,"phases":497,"briefSummary":498,"conditions":499,"keywords":501,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":514},"100623543","discontinuation-of-antiplatelet-therapy-after-drug-coated-balloon-treatment-100623543","NCT07398001","Discontinuation of Antiplatelet Therapy After Drug-Coated Balloon Treatment","Inclusion Criteria:\n\n1. Adults aged 19 years or older who are able to understand the risks, benefits, and treatment alternatives of the study and who provide written informed consent voluntarily.\n2. Patients who underwent drug-coated balloon treatment at least 12 months prior to enrollment.\n3. Patients who have not experienced major adverse cardiovascular events, including myocardial infarction, stroke, or target vessel revascularization, since the index DCB treatment.\n4. Patients who have not experienced major bleeding since the index DCB treatment.\n5. Patients who are receiving antiplatelet therapy at the time of enrollment.\n\nExclusion Criteria:\n\n1. Patients with concomitant vascular disease requiring long-term antiplatelet therapy.\n2. Patients with non-cardiac comorbid conditions that, in the judgment of the investigator, are associated with a life expectancy of less than 1 year or may result in poor compliance with the study protocol.\n3. Patients who are participating in another drug or coronary device clinical study at the time of enrollment.",{"count":496,"type":22},1042,[110],"The goal of this clinical trial is to evaluate the benefits and risks of discontinuing antiplatelet therapy on clinical outcomes in patients who previously underwent coronary intervention using a drug-coated balloon.\n\nThe main questions it aims to answer are:\n\nDoes stopping antiplatelet therapy after 12 months affect the risk of net adverse clinical events? Does stopping antiplatelet therapy reduce the risk of bleeding compared with continuing treatment?\n\nResearchers will compare patients who discontinue antiplatelet therapy with patients who continue antiplatelet therapy to determine the impact on clinical outcomes during follow-up.\n\nParticipants will:\n\nBe randomly assigned to either discontinue or continue antiplatelet therapy Receive routine clinical follow-up through clinic visits or telephone contacts Be monitored for cardiovascular events and bleeding outcomes over time",[28,315,500],"Drug-coated Balloon",[371,502,150,503,504],"drug-coated balloon","antiplatelet therapy","clinical outcomes","2026-02-02",{"date":507,"type":41},"2026-02-09",{"date":509,"type":22},"2026-02-12",{"date":511,"type":22},"2030-07-31",{"name":513,"class":48},"Ulsan University Hospital",7,{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":519,"acronym":520,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":522,"targetDuration":4,"studyType":23,"phases":524,"briefSummary":525,"conditions":526,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":533,"leadSponsor":534,"locationsCount":4},"100622402","phase-4-bivalirudin-versus-heparin-during-pci-in-high-bleeding-risk-patients-with-acute-coronary-syndromes-100622402","NCT07383155","Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes","BRIGHT-HBR","Inclusion Criteria:\n\n* Age ≥18 years\n* Clinical evidence of NSTE-ACS or recent stabilized STEMI (≥48 hours after symptom onset) undergoing PCI\n* The patient meets the ARC criteria for HBR (≥1 major criterion or ≥2 minor criteria)\n* The patient or legal representative has been fully informed and written informed consent has been obtained\n\nExclusion Criteria:\n\n* STEMI patients within 48 hours of symptom onset\n* CABG or PCI within the prior 6 months, including for the present clinical syndrome\n* Cardiogenic shock\n* Coronary artery disease unsuitable for revascularization or requiring CABG\n* Confirmed or suspected aortic dissection\n* Treatment with a glycoprotein IIb\u002FIIIa inhibitor within 2 hours prior to the PCI (use of intravenous heparin prior to or at the time of randomization is acceptable)\n* Allergy to UFH, bivalirudin, aspirin, clopidogrel, ticagrelor, or contrast agents that cannot be adequately pre-medicated, or any prior anaphylaxis to these agents\n* Any non-cardiac conditions with an expected life expectancy of ≤12 months\n* Patients deemed by the investigator to be clinically unsuitable for coronary angiography and PCI, or who are unlikely to be able to comply with the protocol requirements, including medication adherence and follow-up visits",{"count":523,"type":22},5270,[25],"Background. Randomized data on the optimal parenteral anticoagulant during percutaneous coronary intervention (PCI) in high bleeding risk (HBR) patients with acute coronary syndromes (ACS) are lacking.\n\nMethods. BRIGHT-HBR is an investigator-sponsored, open-label, randomized controlled trial comparing bivalirudin vs. unfractionated heparin (UFH) monotherapy in HBR patients with ACS undergoing PCI. A total of 5270 HBR patients with a non-ST-elevation acute coronary syndrome (NSTE-ACS) or recent stabilized ST-segment elevation myocardial infarction (STEMI, ≥48 hours after symptom onset) will be randomized 1:1 to bivalirudin or UFH at 70 sites in China. HBR is defined by the Academic Research Consortium (ARC)-HBR criteria. The primary composite endpoint is net adverse clinical events (NACE) at 30 days, the composite of all-cause death, myocardial infarction, stroke, urgent target-vessel revascularization, or BARC types 2, 3 or 5 bleeding, and the major secondary endpoint is BARC types 2, 3 or 5 bleeding. The study is powered to demonstrate that bivalirudin is superior to UFH monotherapy for NACE in ACS patients with HRB at 30 days after PCI.\n\nConclusions. The BRIGHT-HBR randomized trial aims to provide evidence on whether bivalirudin reduces the incidence of NACE and clinically relevant bleeding compared with UFH monotherapy in patients with ACS who are at HBR undergoing PCI.",[28,527,314,528],"High Bleeding Risk","Anticoagulant Therapy","2026-02-01",{"date":531,"type":41},"2026-02-03",{"date":529,"type":22},{"date":204,"type":22},{"name":535,"class":48},"Shenyang Northern Hospital",{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":542,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":546,"conditions":547,"keywords":548,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":130},"100622016","comparing-the-components-of-composite-endpoints-for-healthcare-providers-and-patients-100622016","NCT07378137","Comparing the Components of Composite Endpoints for Healthcare Providers and Patients","A Preference Study Comparing the Components of Composite Endpoints for Healthcare Providers and Patients With CAD","REC-CHARTENDS","Inclusion Criteria:\n\n1. Patients with acute or chronic coronary syndrome who have undergone percutaneous coronary intervention;\n2. Patients who can understand the purpose of this trial and are willing to participate in the preference questionnaire.\n3. Healthcare providers who treat patients with coronary artery disease.\n\nExclusion Criteria:\n\n1. Aged \\\u003C 18 years;\n2. Inability to understand the questionnaire or presence of cognitive impairment.",{"count":545,"type":22},600,"Clinical trials often employ a composite primary endpoint to increase event rates and enhance trial efficiency. However, analytic approaches to composite endpoints typically assume that the individual components are of similar importance. In practice, a treatment often has different effects on each individual endpoint, leading to uncertainty in interpreting the results of a clinical trial employing a composite primary endpoint.\n\nSome investigators have recommended using a weighted composite endpoint to address these concerns, in which individual components are valued relative to one another. However, data to inform the weighting of individual endpoints, using opinions from both medical staff and patients, remains controversial. Furthermore, prior efforts to weigh composite endpoints have assumed that patients, physicians, and clinical trialists would assign similar values to individual events. If patients value endpoints differently from trialists, this would suggest that efforts to develop weighted composite endpoints may also need to address patient preferences.\n\nIn the current study, we aim to record the weighing of both patients and medical staff towards a composite endpoint frequently used in cardiovascular clinical trials. To better understand the value of each endpoint for patients and medical staff, we quantified the relative severity of each endpoint when compared to death and assessed for rating differences between the two groups. Additionally, we investigated whether endpoint weights varied by the demographic and clinical characteristics of patients and medical staff.",[32,28],[371,549],"composite endpoints","2026-01-22",{"date":552,"type":41},"2026-01-30",{"date":554,"type":41},"2025-08-18",{"date":556,"type":22},"2026-03-01",{"name":558,"class":48},"Xijing Hospital",{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":565,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":566,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":567,"conditions":568,"keywords":569,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":571,"startDateStruct":572,"completionDateStruct":573,"leadSponsor":574,"locationsCount":130},"100622018","study-on-the-preferences-for-pci-implantation-devices-among-doctors-and-patients-100622018","NCT07378163","Study on the Preferences for PCI Implantation Devices Among Doctors and Patients","Study on the Preferences for Percutaneous Coronary Intervention Implantation Devices Among Healthcare Providers and Patients With Coronary Artery Disease","REC-DEVICEPREF",{"count":545,"type":22},"The contemporary percutaneous treatment of coronary artery disease typically involves initial lesion preparation with balloon angioplasty, followed by the deployment of a drug-eluting stent (DES) to provide an immediate scaffold and reduce the long-term risk of restenosis. However, stent implantation continues to present notable challenges, primarily due to the metallic scaffold left behind. Compared to DES, drug-coated balloons (DCB) provide a direct release of antiproliferative drugs into the vessel wall, preventing coronary restenosis after angioplasty and limiting the risk of stent-related events. DCBs are an established treatment option for in-stent restenosis and small vessels. However, the REC-CAGEFREE I trial demonstrated that a strategy of DCB angioplasty with rescue stenting did not achieve non-inferiority compared with the intended DES implantation in patients with de novo, non-complex coronary artery disease (CAD), irrespective of vessel diameter.\n\nPrevious studies have mainly focused on the efficacy of PCI strategies in reducing adverse event rates, while less attention has been paid to patients' willingness regarding stent implantation. The AHA conducted a systematic review on depression and poor prognosis among patients with acute coronary syndrome (ACS), concluding that health organizations should consider depression as an official risk factor for poor prognosis after ACS. A prior study of patients with coronary artery disease after stent implantation found that their anxiety stemmed primarily from concerns about the stent's long-term effects and its impact on their social interaction. However, data regarding patients' preferences on the selection of DES or DCB is scarce, and whether the psychological impact would differ between DES- or DCB-treated patients is still unknown. This study aimed to investigate the preferences of patients, as well as medical staff, for DES or DCB-based PCI.",[32,28],[570,502,147],"Coronary artery disease",{"date":552,"type":41},{"date":554,"type":41},{"date":556,"type":22},{"name":558,"class":48},{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":581,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":18,"minAge":583,"maxAge":4,"enrollmentInfo":584,"targetDuration":586,"studyType":142,"phases":4,"briefSummary":587,"conditions":588,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":130},"100556185","cardio-renal-registry-100556185","NCT06521801","Cardio-Renal Registry","Barts Health Cardio-Renal Registry","BHCRR","Informed consent will not be sought for, as patients are automatically included onto a database that we will use for research purposes. No children will be included in this study. Vulnerable adults or those unable to give consent will be included in the study as well if they are referred to the Nephrology team.\n\nInclusion Criteria:\n\n1. Both male and female patients ≥16 years of age will be included\n2. All patients will be reviewed by the Nephrology team a the RLH with renal disease.\n\nExclusion Criteria:\n\n1\\. Patients \\\u003C16 years will not be included in this study.","16 Years",{"count":585,"type":22},60000,"12 Weeks","Cardiovascular disease is the leading cause of morbidity and mortality among patients with chronic kidney disease (CKD). Even after adjustment for known cardiovascular risk factors, including diabetes and hypertension, mortality risk progressively increases with worsening CKD. As glomerular filtration rate (GFR) declines the probability of developing coronary artery disease (CAD) increases linearly, and patients with GFR \\\u003C60 mL\u002Fmin\u002F1.73 m2 have 2-3-fold increased CV mortality risk, relative to patients without CKD. Management of CAD is complicated in CKD patients due to the likelihood of comorbid conditions and potential for side effects. Despite their high cardiovascular risk, ACS patients with renal dysfunction are less commonly treated with guideline-based medical therapy and are less frequently referred for coronary revascularisation. This observation, referred to as the \"treatment risk paradox,\" has been well described and may be explained by physicians' concerns regarding possible nonrenal side effects as well as renal toxicities. Furthermore, patients with severe CKD have traditionally been under-represented in most large cardiovascular clinical trials. Therefore, recommendations for both medical and revascularisation of CAD have relied heavily on extrapolation of results from the non-CKD population.\n\nThis data will add to that literature by assessing the characteristics and outcomes of patients with CAD and CKD. It will also identify and characterise predictors of outcomes, improve risk stratification and diagnostic evaluation.",[589,590,78,591,28,592],"End Stage Renal Disease","Cardio-Renal Syndrome","Cerebrovascular Accident","Dialysis","2026-01-05",{"date":595,"type":41},"2026-01-07",{"date":597,"type":41},"2024-08-01",{"date":599,"type":22},"2030-06-01",{"name":601,"class":48},"Queen Mary University of London",{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":170,"enrollmentInfo":609,"targetDuration":4,"studyType":23,"phases":611,"briefSummary":612,"conditions":613,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":624},"100618505","digital-remote-management-for-care-and-continuous-optimization-versus-usual-care-in-patients-with-coronary-heart-disease-digicare-chd-100618505","NCT07332494","Digital Remote Management for Care and Continuous Optimization Versus Usual Care in Patients With Coronary Heart Disease (DigiCare-CHD)","DigiCare-CHD","Inclusion Criteria:\n\n1. Age 18-75 years\n2. Diagnosis of Acute Coronary Syndrome (ACS) or Chronic Coronary Syndrome (CCS)\n3. Status post-successful percutaneous coronary intervention (PCI).\n4. Possession of a smartphone and ability to operate the application (independently or with caregiver assistance).\n5. Provision of written informed consent.\n\nExclusion Criteria:\n\n1. Heart Failure: NYHA Class III-IV or LVEF \\\u003C 40%.\n2. Severe hepatic dysfunction (ALT\u002FAST ≥3xULN or Total Bilirubin \\>1.5 mg\u002Fdl)\n3. Severe renal dysfunction (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m² or requiring dialysis)\n4. Uncontrolled hypothyroidism (TSH \\>1.5xULN or \\>10 mIU\u002FL, or unstable dosage within 6 weeks)\n5. Life expectancy \\\u003C 1 year due to non-cardiovascular comorbidities\n6. Severe sensory (hearing\u002Fvision) or cognitive impairment precluding device use\n7. Conditions affecting adherence (e.g., substance use disorder, history of alcohol abuse)",{"count":610,"type":22},792,[110],"The DigiCare-CHD study is an investigator-initiated, multicenter, open-label, parallel-group randomized controlled trial. It aims to evaluated the efficacy of a smartphone-based digital remote management platform compared to usual care in achieving dual goal attainment of blood pressure and LDL-cholesterol levels in patients with coronary heart disease following percutaneous coronary intervention.",[614,28],"Coronary Heart Disease","2025-12-31",{"date":617,"type":41},"2026-01-12",{"date":619,"type":22},"2026-01",{"date":621,"type":22},"2027-07",{"name":623,"class":48},"Beijing Anzhen Hospital",4,{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":631,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":633,"targetDuration":635,"studyType":142,"phases":4,"briefSummary":636,"conditions":637,"keywords":639,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":647,"locationsCount":649},"100618361","polish-registry-of-percutaneous-coronary-intervention-for-chronic-total-occlusions-100618361","NCT07330622","Polish Registry of Percutaneous Coronary Intervention for Chronic Total Occlusions","Polish Registry of Percutaneous Coronary Intervention for Chronic Total Occlusions (POL-CTO Registry)","POL-CTO","Inclusion Criteria:\n\n* Patients undergoing CTO PCI based on clinical grounds\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Patient's refusal to participate in the registry",{"count":634,"type":22},1000,"1 Year","The goal of this observational study is to evaluate the safety, efficacy, and clinical outcomes of percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) in patients treated in contemporary clinical practice in Poland.\n\nThe main questions it aims to answer are:\n\n* What are the rates of procedural success and periprocedural complications of CTO PCI in routine clinical practice?\n* How do CTO PCI strategies and techniques, intravascular imaging, different treatment strategies, and mechanical circulatory support affect clinical outcomes?\n* How do clinical outcomes differ among different patient subgroups?\n* Can artificial intelligence-based analysis predict clinical and quality-of-life outcomes after CTO PCI?\n\nPatients undergoing CTO PCI as part of their standard medical care will be prospectively enrolled in a national, multicenter registry, with clinical, procedural, and follow-up data collected to evaluate real-world outcomes.",[638,28],"Coronary Occlusion",[371,150,640],"coronary chronic total occlusion","2025-12-29",{"date":643,"type":41},"2026-01-09",{"date":645,"type":41},"2025-05-21",{"date":125,"type":22},{"name":648,"class":48},"National Institute of Cardiology, Warsaw, Poland",21,{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":656,"eligibilityCriteria":657,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":658,"targetDuration":4,"studyType":23,"phases":660,"briefSummary":661,"conditions":662,"keywords":663,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":666,"startDateStruct":668,"completionDateStruct":670,"leadSponsor":672,"locationsCount":673},"100583623","antegrade-dissection-and-re-entry-versus-retrograde-strategy-in-cto-pci-100583623","NCT06878729","Antegrade Dissection and Re-entry Versus Retrograde Strategy in CTO PCI","Antegrade Dissection and Re-entry Versus Retrograde Strategy in Chronic Total Occlusion Percutaneous Coronary Intervention","ADRENALINE","Inclusion Criteria:\n\n* clinical indication for CTO PCI as determined by the local heart team (presence of angina or equivalent symptoms and\u002For documented ischemia or viability)\n* at least difficult native CTO lesion with J-CTO difficulty score ≥2 points on invasive angiography\n* angiographic suitability for both ADR and the retrograde strategy as assessed by 2 independent hybrid CTO PCI operators\n* informed consent for participation in the study\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* acute myocardial infarction\n* cardiogenic shock\n* severe valvular disease\n* estimated life expectancy \\\u003C1 year\n* contraindication to PCI\n* contrast allergy\n* positive pregnancy test or breast-feeding\n* native CTO lesion with easy or intermediate difficulty score on invasive angiography (J-CTO score \\\u003C2 points)\n* lack of angiographic equipoise between the ADR and the retrograde strategy as assessed by 2 independent hybrid CTO PCI operators",{"count":659,"type":22},74,[110],"The ADRENALINE trial has been designed as a multi-center, prospective randomized study to compare the procedural and periprocedural outcomes of coronary chronic total occlusion (CTO) percutaneous coronary intervention (PCI) using antegrade dissection and re-entry (ADR) versus retrograde strategy. Beyond the patient-oriented outcomes, the influence of the studied CTO PCI strategies on the stress levels among interventional cardiologists will be explored.\n\nThe main questions it aims to answer are as follows:\n\n* What is the difference between ADR versus retrograde strategy with regard to total procedure time, the rates of successful guidewire crossing and periprocedural complications as well as stress levels experienced by interventional cardiologists?\n* Is retrograde approach associated with higher rates of myocardial injury\u002Finfarction based on cardiac troponin\u002Fcardiac magnetic resonance (CMR) as compared with ADR?\n\nParticipants will undergo pre- and postprocedural laboratory testing (cardiac troponin, CK-MB), CMR for late gadolinium enhancement and health status assessment. Subjects undergoing successful CTO PCI using antegrade wiring strategy will be included in the observational arm.",[32,638,28],[371,150,640,664,665],"antegrade dissection and re-entry","retrograde strategy",{"date":667,"type":41},"2026-01-02",{"date":669,"type":41},"2025-07-28",{"date":671,"type":22},"2028-09-30",{"name":648,"class":48},3]